In particular, AR is emerging as a potential weapon for managing ER-positive and triple-negative breast cancer (TNBC), which prognosis is still considerably poorer compared to the other BC subtypes due to the shortage of therapeutic options [9]. Here, ESR1 is linked to breast cancer.